Orly Eizenberg

Medicine · Health Sciences

17h-index1.5kcitations87works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemokine receptors and signaling(29), Immunotherapy and Immune Responses(22), Multiple Myeloma Research and Treatments(17), Chronic Lymphocytic Leukemia Research(14), Neuroblastoma Research and Treatments(13)

Publications87 total

Abstract A056: Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer
Cancer Research·2025
Abstract 6874: Bkt300, a novel small molecule targeting the protein regulator of cytokinesis 1 pathway in hepatocellular carcinoma
Cancer Research·2025Open Access
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway
2025Open Access
Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway
Cancer Research·2024
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>
2023Open Access
Figure S5 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
2023Open Access
Table S3 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34<sup>+</sup> Cells in Healthy Volunteers
2023Open Access
Figure S1 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
2023Open Access
Data from The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34<sup>+</sup> Cells in Patients with Multiple Myeloma
2023Open Access
Supplementary Figure 2 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
2023Open Access
Figure S3 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
2023Open Access
Table S1 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34<sup>+</sup> Cells in Healthy Volunteers
2023Open Access
Supplementary Figure 4 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Michal Abraham(39), Amnon Peled(39), Hanna Wald(31), Katia Beider(31), Eithan Galun(27), Arnon Nagler(23), Baruch Bulvik(14), Yaron Pereg(14), Shiri Klein(13), Ido D. Weiss(13), Lola Weiss(13), Ori Wald(13), Arnon Aharon(8), Devorah Olam(7), Abraham Avigdor(7), Abi Vainstein(7), Elena Ribakovsky(6), Elia Dery(6), Neta Barashi(6), Rinat Abramovitch(6)